Skip to main content
Genomic medicine for secondary breast cancer: hype or reality?

For some, it’s the next great step forward in secondary breast cancer treatment. For others, the benefits simply aren’t clear enough.
In a hospital clinic, somewhere in the UK, someone awaits the news they never want to hear. “I’m afraid your cancer has returned, and it has spread. The best thing we can do is start treatment right away”.
Unfortunately, this is an all too familiar scene for the thousands of people currently living with secondary breast cancer, and one that can feel like a death sentence. For many of these patients, treatments are ineffective, toxic and in many cases, only serve to extend life rather than cure their disease.
The only reassuring part of the news is that there are treatments available. Chemotherapy is the weapon of choice against most secondary cancers, but using it can be like trying to hit a bullseye with a shotgun.  For all the guidance and evidence there is for picking the best drug, or combination of drugs, to treat primary cancers, doctors still don’t really know what the best practice is for treating secondary breast cancer patients and they often rely on their own clinical experience to guide their decision.

Treating the untreatable

There is hope that advances in our understanding and analysis of the DNA code will lead to new ways to treat the untreatable. The era of the £1,000 genome (the complete DNA code of a person) is upon us and everyone is awaiting the shakeup it will have.
The relatively low cost and speed of decoding a patient’s DNA could now allow doctors to analyze a patient’s secondary tumor, identify its genetic weaknesses that are targetable with drugs (so-called targeted treatments), and treat that patient accordingly.
This is the blueprint for personalized medicine and it might offer the best chance of saving lives.  The question is - are we ready for it? And is this sort of medicine a reality for patients with secondary breast cancer, or is it just hype?
When researchers talk about the issue it soon becomes obvious that whilst we have the technology and the capability to carry out this sort of DNA decoding (known as DNA sequencing) in the clinic, we should be careful not to get ahead of ourselves.
We should speak about this issue in related conferences because the reality is that there are many complex issues such as the number and availability of using targeted treatments which could prevent this information having any actual benefit for the patient.
A study published this year by researchers that they tested the feasibility of using DNA sequencing to direct treatment of secondary breast cancer patients.  They found that 195 of the 423 patients enrolled on the trial had a genetic weakness in their cancer, detected by DNA sequencing, which could potentially be targeted with a specific treatment.  Out of these patients, only 23 (five percent) received any treatment they wouldn’t have had normally, and only 13 (3 percent) received any clinical benefit from the different treatment.
But to some researchers, the fact that any of the patients benefitted from this sort of personalized approach marks the beginning of this sort of approach to treatment.
DNA sequencing has vastly improved our understanding of the genetics of cancer and the fact that we can use this technology in clinical setting shows how far we’ve come since the completion of the Human Genome Project. This technology needs to be nurtured alongside basic research to develop the drugs that match the targets we discover through sequencing.

We have made progress with how we treat secondary breast cancer but we need to do more.  The survival time of two-three years hasn’t changed for the past two decades.
Key Words: Breast Cancer Genomics, Chemotherapy, DNA Sequencing

ENDS

Comments

Post a Comment

Popular posts from this blog

The significance of Probiotic in Breast Milk

The biologic standard of breast milk: The structure of breast milk is the biologic standard for baby nourishment.  Human milk likewise contains thousands of distinct bioactive particles that protect against disease and inflammation and add to immune development, organ improvement, and solid microbial colonization. A portion of these molecules, e.g., lactoferrin, are being explored as novel restorative agents. A dynamic, bioactive fluid, breast milk changes in composition from colostrum to late lactation, and shifts inside feeds, diurnally, and between mothers .  Human milk is high in protein in the first stage after birth, but then protein levels decrease.   The microbiome of breastfed babies made up for a low amount of certain amino acids by expanding the dimensions of microorganisms outfitted with the hereditary programming to synthesize such amino acids – eminently methionine, isoleucine, leucine, valine, cysteine, serine, threonine and arginine. Numerous...
Post a Comment
Read more
Harnessing Sperm to treat Gynaecological Diseases Making a successful method to target disease cells with drugs is trying on different fronts. For instance, the medications don't generally travel profoundly enough through tissues, and they can get weakened in body liquids or derailed taken up by solid organs. To get around these issues, researchers have handed over a few cases to stacking pharmaceuticals into microbes, which can successfully contain sedate mixes and move themselves. The organisms can likewise be guided by an attractive field or other instrument to achieve a particular target. In any case, the body's insusceptible framework can assault the organisms and crush them before they achieve their objective. Searching for another self-pushed cell as an elective medication bearer to microorganisms, Mariana Medina-Sánchez and partners at the Leibniz Institute for Solid State and Materials Research - Dresden (IFW Dresden) swung to sperm. The scientists bundled a ...
Post a Comment
Read more

High-Risk HPV More than Doubles Pregnant Women’s Preeclampsia Risk

Approximately 45% of women ages 20 – 24 are infected with high-risk  human papillomavirus (HPV) .  About 30% of women between the ages of 25 and 40 have high-risk HPV, with the percentage slightly declining among women in their forties.  For sure, high-risk HPV is an extremely normal illness – particularly among ladies in their childbearing years. Ladies infected with high-risk HPV right on time in pregnancy are more than twice as prone to develop preeclampsia. An investigation demonstrates a relationship between high-chance human papillomavirus and preeclampsia, which is steady with the affiliation that was already observed between high-chance HPV and cardiovascular ailment. Utilizing information on the populace predominance of high-chance HPV disease, the scientists evaluated that if all ladies got the quadrivalent immunization (which avoids around 66% of such contaminations); the rate of preeclampsia would tumble from 5,189 to 5,020 case...
Post a Comment
Read more